Hepion Pharmaceuticals replaces auditor Grassi with Rosenberg Rich Baker Berman
HEPA•Hepion Pharmaceuticals dismissed Grassi & Co. effective Sept. 22, 2026, and hired Rosenberg Rich Baker Berman to audit its 2026 consolidated financial statements. Prior audit reports included a going-concern warning, and the company reported material weaknesses in internal controls but no accounting or audit-scope disputes with Grassi.
1. Auditor change
Hepion Pharmaceuticals dismissed Grassi & Co. effective Sept. 22, 2026, and hired Rosenberg Rich Baker Berman to audit its 2026 consolidated financial statements. Prior audit reports included a going-concern warning tied to significant operating losses and negative operating cash flow since inception; the company reported no accounting or audit-scope disputes with Grassi for 2024–2025 or through Sept. 21, 2026. Material weaknesses in internal control over financial reporting were cited as the only reportable events.
